How the multiple burdens of daily oral antiretroviral therapy shape the acceptability of long-acting injectable cabotegravir and rilpivirine among people living with HIV in Uganda and South Africa
A sub-study of the Impala trial
Bibliographic Data
| ID | 24144925 |
|---|---|
| Authors | Dominic Bukenya (0000-0002-6245-8565, London School of Hygiene & Tropical Medicine), Agnes Ssali (0000-0003-4801-0411, London School of Hygiene & Tropical Medicine), Makhosazane Zondi (Centre for the AIDS Programme of Research in South Africa), Eugene Ruzagira (0000-0002-7291-1693, London School of Hygiene & Tropical Medicine), Fiona V Cresswell (0000-0002-5070-532X, Brighton and Sussex Medical School), Nicola Desmond (0000-0002-2874-8569, London School of Hygiene & Tropical Medicine), Janet Seeley (0000-0002-0583-5272, London School of Hygiene & Tropical Medicine, corresponding author), David S Lawrence (0000-0002-5439-4039, University of the Witwatersrand) |
| Year | 2026 |
| Pages | 1-15 |
| Publication date | 2026-09-15 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | AIDS Care (JOURNAL) |
| Journal identifiers | ISSN: 0954-0121 • E-ISSN: 1360-0451 |
| Publisher | Informa UK Limited (PUBLISHER • GB) |
| DOI | 10.1080/09540121.2026.2729655 |
| PMID | 42742090 |
| OpenAlex | W7213354656 |
| Language | EN |
| References cited | 42 |
Long-acting injectable antiretroviral therapy (LAI-ART) has the potential to improve adherence and treatment outcomes among people living with HIV (PLHIV) who experience challenges with adherence to oral medication. We explored how experiences with daily oral ART shaped LAI-ART acceptability within a clinical trial in Uganda and South Africa. A qualitative methods sub-study was nested within a phase 3b randomised clinical trial evaluating long-acting injectable cabotegravir + rilpivirine among PLHIV with a history of suboptimal adherence to oral ART in Uganda and South Africa. Three in-depth interviews (months 1, 6 and 12) were conducted with a purposive sample of 40 participants (divided equally by country and study arm). Data were analysed thematically. Three themes shaped the perceived and experienced acceptability of LAI-ART: Burdens of daily oral ART, including emotional strain, stigma, fear of disclosure, treatment fatigue, mobility constraints, and gendered responsibilities. Experienced benefits of LAI-ART, including convenience, discretion, and reduced reminders of HIV status and the pressure of daily pill-taking. Finally, prior experiences with routine HIV care services were contrasted with trial-based care that emphasised privacy, efficiency, respectful communication, and reimbursement of transportation costs. LAI-ART was preferred to daily oral ART as it reduced treatment burden, improved privacy and supported adherence.
Antiretroviral therapy · Antiretroviral treatment · Clinical trial · Human immunodeficiency virus (HIV) · Medication adherence · Qualitative research · Reimbursement · Rilpivirine · HIV Research and Treatment · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Acceptability of healthcare interventions
Adherence to Haart
Explaining Adherence Success in Sub-Saharan Africa
Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral Suppression
Barriers to ART adherence in sub-Saharan Africa
Gender and stigma in antiretroviral treatment adherence in Mozambique
A scoping review on the role of masculine norms in men’s engagement in the HIV care continuum in sub-Saharan Africa
Differentiated HIV care in sub-Saharan Africa
Therapeutic equivalence, different stigma
Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa
Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States
Dividuality, masculine respectability and reputation
| Citation velocity | historical |
|---|---|
| Highly cited | No |